Study Suggests Reassessment of iNO Treatment Response Time in HRF Newborns Is Needed

2019-03-21T15:37:39-04:00March 21st, 2019|

A recent study published in BMC Pediatrics shows that reliable, objective, early criteria for inhaled nitric oxide (iNO) treatment response in newborns with hypoxic respiratory failure (HRF) still needs to be established. An estimated two percent of babies born in the U.S. are thought to need help breathing using machines. About 35,000 of these

New Online Tool Simplifies Clinical Trial Search

2019-03-13T20:28:27-04:00March 13th, 2019|

The Pulmonary Hypertension Association (PHA) is pleased to announce the launch of its new Clinical Trial Finder, now available in the research section of the PHA website, PHA provides this tool to help participants learn more about ongoing PH research. The tool includes filters to narrow search results to fit an individual’s personal needs.

Updated REVEAL Risk Calculator Improves Accuracy of PAH Survival Predictions

2019-03-07T18:51:45-05:00March 7th, 2019|

A team of researchers has increased the accuracy of a tool used to predict survival for individuals with World Health Organization Group 1 PH (pulmonary arterial hypertension or PAH). CHEST Journal, the official publication of the American College of Chest Physicians, has published a study by Raymond L. Benza, M.D., a cardiologist at Allegheny

Expert Panel Updates PAH Therapy Guidelines

2019-02-21T21:44:57-05:00February 21st, 2019|

Updated guidelines for pulmonary arterial hypertension (PAH) were recently completed by a panel of experts from the Pulmonary Hypertension Association, American Thoracic Society and the American Heart Association and published in the CHEST Journal. The panel, which included several PHA members and a patient representative, looked at 300 recent studies to complete the update

Advances in Pulmonary Hypertension Looks at Different Approaches to Treat Pediatric PH

2019-02-07T19:29:29-05:00February 7th, 2019|

Although the World Symposium on Pulmonary Hypertension (WSPH) has led pulmonary hypertension (PH) to be considered in five classifications, or groups, pediatric PH is more nuanced and there is increasing recognition of unique genotypic and phenotypic subsets of the disease. This necessitates individualized and precision approaches to treatments for children with PH that will

PHA’s Online Advances in Pulmonary Hypertension Examines Barriers in New PH Therapies

2019-01-31T20:19:28-05:00January 31st, 2019|

The latest issue of Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension Association (PHA) — a free quarterly publication directed by an editorial board of renowned pulmonary hypertension (PH) experts — includes an article by Brian Graham, M.D., Peter Fernandes, M. Pharm., and Sue Gu, M.D., that explores the barriers and solutions to

Early Signs of Pulmonary Vascular Disease Found in Adults Born Prematurely

2019-01-24T22:05:08-05:00January 24th, 2019|

One in 10 people in the U.S. is born prematurely. Premature birth is known to be associated with pulmonary vascular disease in infants and children, and registry studies have found those born prematurely are three to five times more likely to develop pulmonary hypertension (PH) as adolescents or young adults. Less is known, however,

Data Collected Through PHA’s Research Room Leads to the Identification of PAH Biomarker

2019-01-10T22:26:08-05:00January 10th, 2019|

Since the first Pulmonary Hypertension Association (PHA) Conference in 1994, the Research Room at PHA’s International PH Conference and Scientific Sessions has offered a dedicated space for individuals with pulmonary hypertension (PH) and their families to participate in research by leading physicians and scientists. This participation furthers the researchers’ studies through the collection of

Is Race a Risk Factor for Pulmonary Hypertension?

2020-07-19T13:32:09-04:00December 13th, 2018|

by Phyllis Hanlon, Contributing Writer Few studies have examined whether race makes a difference in how often pulmonary hypertension (PH) occurs and what causes it. These questions prompted a specialist team at Vanderbilt University Medical Center, an accredited Pulmonary Hypertension Care Center (PHCC), to explore the issue. Overall, the team found that the African

Researchers at Vanderbilt Publish First Study from PHA’s 2018 Research Room

2020-07-19T13:31:15-04:00November 29th, 2018|

Using fitness devices and cell phones, pulmonary hypertension (PH) researchers compared the physical activity of individuals with and without pulmonary arterial hypertension (PAH) in the first research study published using data collected through the Research Room at the Pulmonary Hypertension Association’s (PHA’s) 2018 International PH Conference and Scientific Sessions in Orlando, Fla. By collecting